Parasitic sirtuin 2 as an opportunity in drug discovery

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Scotti L, Scotti MT. Neglected diseases – new compounds and treatments. Curr. Med. Chem. 27(5), 659–661 (2020).
  Medline CASGoogle Scholar
• 2. Hotez PJ. The poverty-related neglected diseases: why basic research matters. PLoS Biol. 15(11), e2004186 (2017).
  MedlineGoogle Scholar
• 3. Weng H-B, Chen H-X, Wang M-W. Innovation in neglected tropical disease drug discovery and development. Infect. Dis. Poverty. 7(1), 67 (2018).
  MedlineGoogle Scholar
• 4. Maya JD, Cassels BK, Iturriaga-Vásquez P et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp. Biochem. Physiol. Part A Mol. Integr. Physiol. 146(4), 601–620 (2007).
  MedlineGoogle Scholar
• 5. Boiani M, Piacenza L, Hernández P et al. Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved? Biochem. Pharmacol. 79(12), 1736–1745 (2010).
  Medline CASGoogle Scholar
• 6. Babokhov P, Sanyaolu AO, Oyibo WA et al. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog. Glob. Health. 107(5), 242–252 (2013).
  Medline CASGoogle Scholar
• 7. De Koning PH. The drugs of sleeping sickness: their mechanisms of action and resistance, and a brief history. Trop. Med. Infect. Dis. 5(1), 14 (2020).
  Google Scholar
• 8. Lindner AK, Lejon V, Chappuis F et al. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infect. Dis. 20(2), e38–e46 (2020).
  Medline CASGoogle Scholar
• 9. Fairlamb AH, Horn D. Melarsoprol resistance in African trypanosomiasis. Trends Parasitol. 34(6), 481–492 (2018).
  Medline CASGoogle Scholar
• 10. Thomas J, Baker N, Hutchinson S et al. Insights into antitrypanosomal drug mode-of-action from cytology-based profiling. PLoS Negl. Trop. Dis. 12(11), e0006980 (2018).
  Medline CASGoogle Scholar
• 11. Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br. J. Pharmacol. 152(8), 1155–1171 (2007).
  Medline CASGoogle Scholar
• 12. Priotto G, Kasparian S, Mutombo W et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 374(9683), 56–64 (2009).
  Medline CASGoogle Scholar
• 13. Taylor WRJ, Thriemer K, von Seidlein L et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 394(10202), 929–938 (2019).
  Medline CASGoogle Scholar
• 14. Ocan M, Akena D, Nsobya S et al. Persistence of chloroquine resistance alleles in malaria endemic countries: a systematic review of burden and risk factors. Malar. J. 18(1), 76 (2019).
  MedlineGoogle Scholar
• 15. Wicht KJ, Mok S, Fidock DA. Molecular mechanisms of drug resistance in Plasmodium falciparum malaria. Annu. Rev. Microbiol. 74, 431–454 (2020).
  Medline CASGoogle Scholar
• 16. Kimutai R, Musa AM, Njoroge S et al. Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern Africa: results from a pharmacovigilance programme. Clin. Drug Investig. 37(3), 259–272 (2017).
  Medline CASGoogle Scholar
• 17. Frézard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules. 14(7), 2317–2336 (2009).
  Medline CASGoogle Scholar
• 18. Hendrickx S, Caljon G, Maes L. Need for sustainable approaches in antileishmanial drug discovery. Parasitol. Res. 118(10), 2743–2752 (2019).
  MedlineGoogle Scholar
• 19. Religa AA, Waters AP. Sirtuins of parasitic protozoa: in search of function (s). Mol. Biochem. Parasitol. 185(2), 71–88 (2012).
  Medline CASGoogle Scholar
• 20. Carafa V, Rotili D, Forgione M et al. Sirtuin functions and modulation: from chemistry to the clinic. Clin. Epigenetics. 8(1), 61 (2016).
  MedlineGoogle Scholar
• 21. Ali I, Conrad RJ, Verdin E, Ott M. Lysine acetylation goes global: from epigenetics to metabolism and therapeutics. Chem. Rev. 118(3), 1216–1252 (2018). •• Authors explain in detail the mechanism of catalysed deacetilation performed by sirtuins.
  Medline CASGoogle Scholar
• 22. McIntyre RL, Daniels EG, Molenaars M et al. From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs. EMBO Mol. Med. 11(9), e9854 (2019).
  MedlineGoogle Scholar
• 23. Hu F, Sun X, Li G et al. Inhibition of SIRT2 limits tumour angiogenesis via inactivation of the STAT3/VEGFA signalling pathway. Cell Death Dis. 10(1), 1–14 (2018).
  MedlineGoogle Scholar
• 24. Zhou S, Tang X, Chen H-Z. Sirtuins and insulin resistance. Front. Endocrinol. (Lausanne). 9, 748 (2018).
  MedlineGoogle Scholar
• 25. Zhang Y, Anoopkumar-Dukie S, Arora D, Davey AK. Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases. Eur. J. Pharmacol. 867, 172847 (2020).
  Medline CASGoogle Scholar
• 26. Singh P, Hanson PS, Morris CM. Sirtuin-2 protects neural cells from oxidative stress and is elevated in neurodegeneration. Park. Dis. 2017, (2017).
  MedlineGoogle Scholar
• 27. Tang X, Chen X-F, Wang N-Y et al. SIRT2 acts as a cardioprotective deacetylase in pathological cardiac hypertrophy. Circulation. 136(21), 2051–2067 (2017).
  Medline CASGoogle Scholar
• 28. Mei Z, Wang H, Hu Y, Xiong L. CSN6 aggravates Ang II-induced cardiomyocyte hypertrophy via inhibiting SIRT2. Exp. Cell Res. 396(1), 112245 (2020).
  Medline CASGoogle Scholar
• 29. Jin J, He B, Zhang X, Lin H, Wang Y. SIRT2 reverses 4-oxononanoyl lysine modification on histones. J. Am. Chem. Soc. 138(38), 12304–12307 (2016).
  Medline CASGoogle Scholar
• 30. Sarikhani M, Mishra S, Desingu PA et al. SIRT2 regulates oxidative stress-induced cell death through deacetylation of c-Jun NH 2-terminal kinase. Cell Death Differ. 25(9), 1638–1656 (2018).
  Medline CASGoogle Scholar
• 31. Zhou W, Ni TK, Wronski A et al. The SIRT2 deacetylase stabilizes slug to control malignancy of basal-like breast cancer. Cell Rep. 17(5), 1302–1317 (2016).
  Medline CASGoogle Scholar
• 32. Kozako T, Mellini P, Ohsugi T et al. Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines. BMC Cancer. 18(1), 1–10 (2018).
  MedlineGoogle Scholar
• 33. Quan S, Principe DR, Dean AE et al. Loss of Sirt2 increases and prolongs a caerulein-induced pancreatitis permissive phenotype and induces spontaneous oncogenic Kras mutations in mice. Sci. Rep. 8(1), 1–15 (2018).
  MedlineGoogle Scholar
• 34. Yahiaoui B, Taibi A, Ouaissi A. A Leishmania major protein with extensive homology to silent information regulator 2 of Saccharomyces cerevisiae. Gene. 169(1), 115–118 (1996).
  Medline CASGoogle Scholar
• 35. Wyllie S, Brand S, Thomas M et al. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proc. Natl. Acad. Sci. 116(19), 9318–9323 (2019).
  Medline CASGoogle Scholar
• 36. Abeijon C, Alves F, Monnerat S et al. Development of a multiplexed assay for detection of Leishmania donovani and Leishmania infantum protein biomarkers in urine samples of patients with visceral leishmaniasis. J. Clin. Microbiol. 57(5), (2019).
  MedlineGoogle Scholar
• 37. Ponte-Sucre A, Gamarro F, Dujardin J-C et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl. Trop. Dis. 11(12), e0006052 (2017).
  MedlineGoogle Scholar
• 38. Borsari C, Jiménez-Antón MD, Eick J et al. Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. Eur. J. Med. Chem. 183, 111676 (2019).
  MedlineGoogle Scholar
• 39. Mittal N, Muthuswami R, Madhubala R. The mitochondrial SIR2 related protein 2 (SIR2RP2) impacts Leishmania donovani growth and infectivity. PLoS Negl. Trop. Dis. 11(5), e0005590 (2017).
  MedlineGoogle Scholar
• 40. Ronin C, Costa DM, Tavares J et al. The crystal structure of the Leishmania infantum Silent Information Regulator 2 related protein 1: implications to protein function and drug design. PLoS ONE 13(3), e0193602 (2018).
  MedlineGoogle Scholar
• 41. Tavares J, Ouaissi A, Santarém N et al. The Leishmania infantum cytosolic SIR2-related protein 1 (LiSIR2RP1) is an NAD+-dependent deacetylase and ADP-ribosyltransferase. Biochem. J. 415(3), 377–386 (2008).
  Medline CASGoogle Scholar
• 42. Vergnes B, Gazanion E, Grentzinger T. Functional divergence of SIR2 orthologs between trypanosomatid parasites. Mol. Biochem. Parasitol. 207(2), 96–101 (2016).
  Medline CASGoogle Scholar
• 43. Kelly JM, Taylor MC, Horn D et al. Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei. Bioorg. Med. Chem. Lett. 22(5), 1886–1890 (2012).
  Medline CASGoogle Scholar
• 44. Ponte-Sucre A. An overview of Trypanosoma brucei infections: an intense host–parasite interaction. Front. Microbiol. 7, 2126 (2016).
  MedlineGoogle Scholar
• 45. Alsford S, Kawahara T, Isamah C, Horn D. A sirtuin in the African trypanosome is involved in both DNA repair and telomeric gene silencing but is not required for antigenic variation. Mol. Microbiol. (2007).
  MedlineGoogle Scholar
• 46. Ritagliati C, Alonso VL, Manarin R et al. Overexpression of cytoplasmic Tc SIR2RP1 and mitochondrial Tc SIR2RP3 impacts on Trypanosoma cruzi ©. PLoS Negl Trop Dis. 9(4), e0003725 (2015).
  MedlineGoogle Scholar
• 47. Gaspar L, Coron RP, KongThoo Lin P et al. Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease. PLoS Negl. Trop. Dis. 12(1), e0006180 (2018).
  MedlineGoogle Scholar
• 48. Moretti NS, da Silva Augusto L, Clemente TM et al. Characterization of Trypanosoma cruzi sirtuins as possible drug targets for Chagas disease. Antimicrob. Agents Chemother. 59(8), 4669–4679 (2015).
  Medline CASGoogle Scholar
• 49. Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat. Med. 23(8), 917 (2017).
  Medline CASGoogle Scholar
• 50. Zhang X, Alexander N, Leonardi I, Mason C, Kirkman LA, Deitsch KW. Rapid antigen diversification through mitotic recombination in the human malaria parasite Plasmodium falciparum. PLoS Biol. 17(5), e3000271 (2019).
  Medline CASGoogle Scholar
• 51. Duraisingh MT, Voss TS, Marty AJ et al. Heterochromatin silencing and locus repositioning linked to regulation of virulence genes in Plasmodium falciparum. Cell. 121(1), 13–24 (2005).
  Medline CASGoogle Scholar
• 52. Coleman BI, Skillman KM, Jiang RHY et al. A Plasmodium falciparum histone deacetylase regulates antigenic variation and gametocyte conversion. Cell Host Microbe. 16(2), 177–186 (2014).
  Medline CASGoogle Scholar
• 53. da Silva VBR, Campos BRKL, de Oliveira JF, Decout J-L, de Lima M do CA. Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine. Bioorg. Med. Chem. 25(13), 3259–3277 (2017).
  MedlineGoogle Scholar
• 54. da Paixão Siqueira L, Fontes DAF, Aguilera CSB et al. Schistosomiasis: drugs used and treatment strategies. Acta Trop. 176, 179–187 (2017).
  MedlineGoogle Scholar
• 55. Lancelot J, Caby S, Dubois-Abdesselem F et al. Schistosoma mansoni sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl Trop Dis. 7(9), e2428 (2013).
  MedlineGoogle Scholar
• 56. Monaldi D, Rotili D, Lancelot J et al. Structure–reactivity relationships on substrates and inhibitors of the lysine deacylase sirtuin 2 from Schistosoma mansoni (Sm Sirt2). J. Med. Chem. 62(19), 8733–8759 (2019).
  Medline CASGoogle Scholar
• 57. Mancio-Silva L, Lopez-Rubio JJ, Claes A, Scherf A. Sir2a regulates rDNA transcription and multiplication rate in the human malaria parasite Plasmodium falciparum. Nat. Commun. 4(1), 1–6 (2013).
  Google Scholar
• 58. Lancelot J, Cabezas-Cruz A, Caby S et al. Schistosome sirtuins as drug targets. Future Med. Chem. 7(6), 765–782 (2015).
  CASGoogle Scholar
• 59. Grozinger CM, Chao ED, Blackwell HE et al. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276(42), 38837–38843 (2001).
  Medline CASGoogle Scholar
• 60. Heltweg B, Gatbonton T, Schuler AD et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66(8), 4368–4377 (2006).
  Medline CASGoogle Scholar
• 61. Lara E, Mai A, Calvanese V et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 28(6), 781–791 (2009).
  Medline CASGoogle Scholar
• 62. Brana MF, Ramos A. Naphthalimides as anticancer agents: synthesis and biological activity. Curr. Med. Chem. Agents. 1(3), 237–255 (2001).
  Medline CASGoogle Scholar
• 63. Hailu GS, Robaa D, Forgione M et al. Lysine deacetylase inhibitors in parasites: past, present, and future perspectives. J. Med. Chem. 60(12), 4780–4804 (2017). •• A complete and extensive review article about lysine deacetilase inhibitors for parasitic diseases.
  Medline CASGoogle Scholar
• 64. Mai A, Massa S, Lavu S et al. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J. Med. Chem. 48(24), 7789–7795 (2005).
  Medline CASGoogle Scholar
• 65. Olaharski AJ, Rine J, Marshall BL et al. The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet. 1(6), e77 (2005).
  MedlineGoogle Scholar
• 66. Dadashpour S, Emami S. Indole in the target-based design of anticancer agents: a versatile scaffold with diverse mechanisms. Eur. J. Med. Chem. 150, 9–29 (2018).
  Medline CASGoogle Scholar
• 67. Bedalov A, Gatbonton T, Irvine WP et al. Identification of a small molecule inhibitor of Sir2p. Proc. Natl Acad. Sci. 98(26), 15113–15118 (2001).
  Medline CASGoogle Scholar
• 68. Zhang Y, Au Q, Zhang M et al. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem. Biophys. Res. Commun. 386(4), 729–733 (2009).
  Medline CASGoogle Scholar
• 69. Mellini P, Carafa V, Di Rienzo B et al. Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies. ChemMedChem. 7(11), 1905–1908 (2012).
  Medline CASGoogle Scholar
• 70. Disch JS, Evindar G, Chiu CH et al. Discovery of thieno [3, 2-d] pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3. J. Med. Chem. 56(9), 3666–3679 (2013).
  Medline CASGoogle Scholar
• 71. Gertz M, Fischer F, Nguyen GTT et al. Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc. Natl Acad. Sci. 110(30), E2772–E2781 (2013). •• Discovery of Ex-527, an uncompetitive/non-competitive inhibitor of Sir2 of Thermotoga maritima in relation to peptide substrate and NAD+, respectively.
  Medline CASGoogle Scholar
• 72. Matutino Bastos T, Mannochio Russo H, Silvio Moretti N et al. Chemical constituents of Anacardium occidentale as inhibitors of Trypanosoma cruzi sirtuins. Molecules. 24(7), 1299 (2019).
  Google Scholar
• 73. Matutino Bastos T, Botelho Pereira Soares M, Haddad Franco C et al. Identification of inhibitors to Trypanosoma cruzi sirtuins based on compounds developed to human enzymes. Int. J. Mol. Sci. 21(10), 3659 (2020). • In vitro tests of Sir2 inhibitors in combination with benznidazole against T. cruzi.
  Google Scholar
• 74. Garcia-Castro M, Zimmermann S, Sankar MG, Kumar K. Scaffold diversity synthesis and its application in probe and drug discovery. Angew. Chemie Int. Ed. 55(27), 7586–7605 (2016).
  Medline CASGoogle Scholar
• 75. Feldman JL, Peterson CL. Yeast sirtuin family members maintain transcription homeostasis to ensure genome stability. Cell Rep. 27(10), 2978–2989 (2019).
  Medline CASGoogle Scholar
• 76. Wang Y, Zhang H, Gigant B et al. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery. FEBS J. 283(1), 102–111 (2016).
  Medline CASGoogle Scholar
• 77. Miana GE, Ribone SR, Vera DMA, Sánchez-Moreno M, Mazzieri MR, Quevedo MA. Design, synthesis and molecular docking studies of novel N-arylsulfonyl-benzimidazoles with anti Trypanosoma cruzi activity. Eur. J. Med. Chem. 165, 1–10 (2019).
  Medline CASGoogle Scholar
• 78. Palma LC, Ferreira LFGR, Petersen AL de OA et al. A docking-based structural analysis of geldanamycin-derived inhibitor binding to human or Leishmania Hsp90. Sci. Rep. 9(1), 1–9 (2019). • Successful application of in silico techniques in combination with in vitro validation for discovery of potent and selective antimicrobials.
  MedlineGoogle Scholar
• 79. Madeira F, Park YM, Lee J et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 47(W1), W636–W641 (2019).
  Medline CASGoogle Scholar
• 80. Blaazer AR, Singh AK, De Heuvel E et al. Targeting a subpocket in Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) enables the structure-based discovery of selective inhibitors with trypanocidal activity. J. Med. Chem. 61(9), 3870–3888 (2018).
  Medline CASGoogle Scholar
• 81. Trapero A, Pacitto A, Singh V et al. Fragment-based approach to targeting Inosine-5′-monophosphate dehydrogenase (IMPDH) from Mycobacterium tuberculosis. J. Med. Chem. 61(7), 2806–2822 (2018).
  Medline CASGoogle Scholar
• 82. Whitehouse AJ, Thomas SE, Brown KP et al. Development of inhibitors against Mycobacterium abscessus tRNA (m1G37) methyltransferase (TrmD) using fragment-based approaches. J. Med. Chem. 62(15), 7210–7232 (2019).
  Medline CASGoogle Scholar
• 83. Penzo M, de Las Heras-Dueña L, Mata-Cantero L et al. High-throughput screening of the Plasmodium falciparum cGMP-dependent protein kinase identified a thiazole scaffold which kills erythrocytic and sexual stage parasites. Sci. Rep. 9(1), 1–13 (2019).
  Medline CASGoogle Scholar
• 84. Durieu E, Prina E, Leclercq O et al. From drug screening to target deconvolution: a target-based drug discovery pipeline using Leishmania casein kinase 1 isoform 2 to identify compounds with antileishmanial activity. Antimicrob. Agents Chemother. 60(5), 2822–2833 (2016).
  Medline CASGoogle Scholar
• 85. Harupa A, De Las Heras L, Colmenarejo G et al. Identification of selective inhibitors of Plasmodium N-myristoyltransferase by high-throughput screening. J. Med. Chem. 63(2), 591–600 (2019).
  Google Scholar
• 86. Delves MJ, Miguel-Blanco C, Matthews H et al. A high throughput screen for next-generation leads targeting malaria parasite transmission. Nat. Commun. 9(1), 1–13 (2018).
  Medline CASGoogle Scholar
• 87. Lawson M, Uciechowska U, Schemies J et al. Inhibitors to understand molecular mechanisms of NAD+-dependent deacetylases (sirtuins). Biochim. Biophys. Acta (BBA)-Gene Regul. Mech. 1799(10–12), 726–739 (2010).
  Medline CASGoogle Scholar
• 88. Yoon YK, Ali MA, Wei AC et al. Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities. Bioorg. Med. Chem. 22(2), 703–710 (2014).
  Medline CASGoogle Scholar
• 89. Mahajan SS, Scian M, Sripathy S et al. Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J. Med. Chem. 57(8), 3283–3294 (2014).
  Medline CASGoogle Scholar
• 90. Yoon YK, Ali MA, Wei AC et al. Benzimidazoles as new scaffold of sirtuin inhibitors: green synthesis, in vitro studies, molecular docking analysis and evaluation of their anti-cancer properties. Eur. J. Med. Chem. 83, 448–454 (2014).
  Medline CASGoogle Scholar
• 91. Carrillo AK, Guiguemde WA, Guy RK. Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). Bioorg. Med. Chem. 23(16), 5151–5155 (2015).
  Medline CASGoogle Scholar
• 92. Filardy AA, Guimarães-Pinto K, Nunes MP et al. Human kinetoplastid protozoan infections: where are we going next? Front. Immunol. 9, 1493 (2018).
  MedlineGoogle Scholar
• 93. Zuma AA, de Souza W. Histone deacetylases as targets for antitrypanosomal drugs. Futur. Sci. OA. 4(8), FSO325 (2018).
  Google Scholar